GLP-1RAs work by activating receptors in the central nervous system that regulate hunger but also impact reward pathways involved in addiction. They influence neurotransmitter systems such as dopamine, glutamate, and GABA within the mesocorticolimbic circuit, which plays a pivotal role in reinforcing addictive behaviors. Additionally, these drugs communicate via the gut-brain axis through vagal afferents, integrating energy balance and motivational signals to curb substance-seeking behavior.
The study reviewed preclinical animal research and early clinical trials. One randomized controlled trial found that semaglutide reduced alcohol self-administration and craving in individuals with alcohol use disorder, especially those with obesity. Rodent models demonstrated that GLP-1RAs reduced heroin, fentanyl, and nicotine self-administration and relapse behavior. Initial clinical data on tobacco use disorder suggests these drugs help decrease cigarettes per day and prevent post-cessation weight gain.
Despite such encouraging findings, challenges remain including variability in drug penetration into the brain and potential side effects like nausea or mood changes. Researchers emphasize the need for larger, well-controlled human trials to establish efficacy, dosing, safety, and long-term outcomes. Lead researcher Dr. Lorenzo Leggio highlighted the importance of these agents as potential game-changers in addiction treatment, offering a novel, neurobiologically based approach that intersects metabolic and psychiatric care.
Overall, GLP-1RAs represent a hopeful new class of addiction therapeutics, targeting core brain mechanisms to reduce substance use and improve overall health outcomes.
Reference: Nirupam M Srinivasan, Mehdi Farokhnia, Lisa A Farinelli, Anna Ferrulli, Lorenzo Leggio. GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer. Journal of the Endocrine Society, 2025; 9 (11) DOI: 10.1210/jendso/bvaf141
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.